Drug Trial Radar · NCT01321827
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
Last checked: Nov 19, 2026Latest source record: Mar 16, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Apr 2011
Primary completion
Mar 2013
Study completion Dec 2015
Sponsor
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 24, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of itraconazole monotherapy in patients with ABPA.
Conditions
- Allergic Bronchopulmonary Aspergillosis
Interventions
GlucocorticoidsDrug
Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
ItraconazoleDrug
Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
Primary outcomes
What the sponsor says the trial is designed to measure.
- Remission rates in the two groups at six weeks and three monthsTime frame: 6 weeks, 3 months
- Percentage decline in IgE levels at six weeks and three monthsTime frame: 6 weeks, 3 months
- Complete remission rates in the two groupsTime frame: 3 months, 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Postgraduate Institute of Medical Education and Research
Chandigarh, Uttarakhand, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.